188 related articles for article (PubMed ID: 26661444)
1. The use of biomarkers in the diagnosis and treatment of overactive bladder: Can we predict the patients who will be resistant to treatment?
Alkis O; Zumrutbas AE; Toktas C; Aybek H; Aybek Z
Neurourol Urodyn; 2017 Feb; 36(2):390-393. PubMed ID: 26661444
[TBL] [Abstract][Full Text] [Related]
2. Urinary neurotrophic peptides in postmenopausal women with and without overactive bladder.
Pennycuff JF; Schutte SC; Hudson CO; Karp DR; Malykhina AP; Northington GM
Neurourol Urodyn; 2017 Mar; 36(3):740-744. PubMed ID: 27062604
[TBL] [Abstract][Full Text] [Related]
3. Urinary nerve growth factor and a variable solifenacin dosage in patients with an overactive bladder.
Ciftci S; Ozkurkcugil C; Yilmaz H; Ustuner M; Yavuz U; Yuksekkaya M; Cekmen MB
Int Urogynecol J; 2016 Feb; 27(2):275-80. PubMed ID: 26310546
[TBL] [Abstract][Full Text] [Related]
4. Urinary brain-derived neurotrophic factor: a potential biomarker for objective diagnosis of overactive bladder.
Wang LW; Han XM; Chen CH; Ma Y; Hai B
Int Urol Nephrol; 2014 Feb; 46(2):341-7. PubMed ID: 23982767
[TBL] [Abstract][Full Text] [Related]
5. The profile of urinary biomarkers in overactive bladder.
Rada MP; Ciortea R; Măluţan AM; Doumouchtsis SK; Bucuri CE; Clim A; Roman A; Mihu D
Neurourol Urodyn; 2020 Nov; 39(8):2305-2313. PubMed ID: 32813897
[TBL] [Abstract][Full Text] [Related]
6. NGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndrome.
Kim SR; Moon YJ; Kim SK; Bai SW
Yonsei Med J; 2015 Jan; 56(1):204-11. PubMed ID: 25510766
[TBL] [Abstract][Full Text] [Related]
7. Bladder wall thickness in women with symptoms of overactive bladder and detrusor overactivity: Results from the randomised, placebo-controlled shrink study.
Robinson D; Oelke M; Khullar V; Wijkstra H; Tretter R; Stow B; Compion G; Tubaro A
Neurourol Urodyn; 2016 Sep; 35(7):819-25. PubMed ID: 26199198
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
[TBL] [Abstract][Full Text] [Related]
9. The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment.
Chou EC; Hung MJ; Yen TW; Chuang YC; Meng E; Huang ST; Kuo HC
J Formos Med Assoc; 2014 Aug; 113(8):506-12. PubMed ID: 25037757
[TBL] [Abstract][Full Text] [Related]
10. Acupuncture versus solifenacin for treatment of overactive bladder and its correlation with urine nerve growth factor levels: a randomized, placebo-controlled clinical trial.
Aydoğmuş Y; Sunay M; Arslan H; Aydın A; Adiloğlu AK; Şahin H
Urol Int; 2014; 93(4):437-43. PubMed ID: 25033919
[TBL] [Abstract][Full Text] [Related]
11. Novel biomarkers of overactive bladder syndrome.
Wróbel AF; Kluz T; Surkont G; Wlaźlak E; Skorupski P; Filipczak A; Rechberger T
Ginekol Pol; 2017; 88(10):568-573. PubMed ID: 29192418
[TBL] [Abstract][Full Text] [Related]
12. Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)?
Seth JH; Sahai A; Khan MS; van der Aa F; de Ridder D; Panicker JN; Dasgupta P; Fowler CJ
BJU Int; 2013 Mar; 111(3):372-80. PubMed ID: 23444927
[TBL] [Abstract][Full Text] [Related]
13. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
[TBL] [Abstract][Full Text] [Related]
14. Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial.
Herdman M; Nazir J; Hakimi Z; Siddiqui E; Huang M; Pavesi M; MacDiarmid S; Drake MJ; Devlin N
Patient; 2017 Dec; 10(6):677-686. PubMed ID: 28646416
[TBL] [Abstract][Full Text] [Related]
15. Urinary Nerve Growth Factor Can Predict Therapeutic Efficacy in Children With Overactive Bladder.
Fukui S; Aoki K; Morizawa Y; Miyake M; Fujimoto K
Urology; 2017 May; 103():214-217. PubMed ID: 28161379
[TBL] [Abstract][Full Text] [Related]
16. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease.
Zesiewicz TA; Evatt M; Vaughan CP; Jahan I; Singer C; Ordorica R; Salemi JL; Shaw JD; Sullivan KL;
Parkinsonism Relat Disord; 2015 May; 21(5):514-20. PubMed ID: 25814050
[TBL] [Abstract][Full Text] [Related]
17. The use of urinary biomarkers in the diagnosis of overactive bladder in female patients. A systematic review and meta-analysis.
Tsiapakidou S; Apostolidis A; Pantazis K; Grimbizis GF; Mikos T
Int Urogynecol J; 2021 Dec; 32(12):3143-3155. PubMed ID: 34363496
[TBL] [Abstract][Full Text] [Related]
18. Urinary brain-derived neurotrophic factor and nerve growth factor as noninvasive biomarkers of overactive bladder in children.
Colic M; Rogic D; Lenicek Krleza J; Kozmar A; Stemberger Maric L; Abdovic S
Biochem Med (Zagreb); 2022 Oct; 32(3):030706. PubMed ID: 36277428
[TBL] [Abstract][Full Text] [Related]
19. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy.
Liu HT; Lin H; Kuo HC
Neurourol Urodyn; 2011 Nov; 30(8):1525-9. PubMed ID: 21826717
[TBL] [Abstract][Full Text] [Related]
20. A randomized, multicenter, controlled study, comparing efficacy and safety of a new complementary and alternative medicine (CAM) versus Solifenacin Succinate in women with overactive bladder syndrome.
Vecchioli-Scaldazza C; Morosetti C; Maruccia S; Casellato S; Rociola W; Illiano E; Garofalo F
Arch Ital Urol Androl; 2017 Dec; 89(4):296-300. PubMed ID: 29473382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
